Abstract
Phisiological activation of PI3K pathway is necessary for cells to regulate many different physiological processes such as transcription, protein synthesis, metabolic responses and membrane trafficking. Abnormal activation of the PI3K pathway leads to an increased activity resulting in tumor onset, maintenance, progression and invasion. Both genetic and epigenetic alterations could affect the normal pathways activation. Ovarian cancer is the leading cause of death from gynaecological malignancies in the western world. PI3K pathway has been recorded as one of the most deregulated signalling pathway in many tumors, including ovarian ones. So it could be considered an attractive target to be investigated with the various classes of chemical compounds already present or in development. In this rewiew well try to discuss the published data of the inhibitors targeting members of the PI3K/ akt/ mTOR pathway in the ovarian cancer setting from a preclinical and clinical point of view, with particular emphasis on drugs combination and strategies of administration. Relevant issues and limitations to the use of particular compounds will be also addressed.
Keywords: PI3K, mTOR, anti-cancer drugs, drug combination, gynaecological malignancies, Ovarian cancer, malignancy, receptor tyrosine kinases (RTKs), G protein-coupled receptors, phosphorylate phosphoinositides (PIs), Pleckstrin Homology, tuberous sclerosis, signaling nodes, PI3K INHIBITORS, synergistic effects, paclitaxel, carboplatin, tumor xenografts, glucose homeostasis, phosphoinositide, API-2, macrolide Rapamycin, bevacizumab, Topotecan, pegylated doxorubicin, PI3K-like kinase (PIKK), chemotherapy, angiogenesis, hypoxia, metformin, rapalogs, regimens
Current Medicinal Chemistry
Title: PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Volume: 17 Issue: 36
Author(s): M. Mazzoletti and M. Broggini
Affiliation:
Keywords: PI3K, mTOR, anti-cancer drugs, drug combination, gynaecological malignancies, Ovarian cancer, malignancy, receptor tyrosine kinases (RTKs), G protein-coupled receptors, phosphorylate phosphoinositides (PIs), Pleckstrin Homology, tuberous sclerosis, signaling nodes, PI3K INHIBITORS, synergistic effects, paclitaxel, carboplatin, tumor xenografts, glucose homeostasis, phosphoinositide, API-2, macrolide Rapamycin, bevacizumab, Topotecan, pegylated doxorubicin, PI3K-like kinase (PIKK), chemotherapy, angiogenesis, hypoxia, metformin, rapalogs, regimens
Abstract: Phisiological activation of PI3K pathway is necessary for cells to regulate many different physiological processes such as transcription, protein synthesis, metabolic responses and membrane trafficking. Abnormal activation of the PI3K pathway leads to an increased activity resulting in tumor onset, maintenance, progression and invasion. Both genetic and epigenetic alterations could affect the normal pathways activation. Ovarian cancer is the leading cause of death from gynaecological malignancies in the western world. PI3K pathway has been recorded as one of the most deregulated signalling pathway in many tumors, including ovarian ones. So it could be considered an attractive target to be investigated with the various classes of chemical compounds already present or in development. In this rewiew well try to discuss the published data of the inhibitors targeting members of the PI3K/ akt/ mTOR pathway in the ovarian cancer setting from a preclinical and clinical point of view, with particular emphasis on drugs combination and strategies of administration. Relevant issues and limitations to the use of particular compounds will be also addressed.
Export Options
About this article
Cite this article as:
Mazzoletti M. and Broggini M., PI3K/AKT/mTOR Inhibitors In Ovarian Cancer, Current Medicinal Chemistry 2010; 17 (36) . https://dx.doi.org/10.2174/092986710794182999
DOI https://dx.doi.org/10.2174/092986710794182999 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Biological Study of Novel Indole-3-Imine-2-on Derivatives as Src Kinase and Glutathione S-Transferase Inhibitors
Letters in Drug Design & Discovery Prospects of Primary Ovarian Insufficiency Patient-Specific Pluripotent Stem Cells for Disease Modeling and Clinical Impacts
Current Women`s Health Reviews In Vitro and In Vivo Investigations into the Carbene Gold Chloride and Thioglucoside Anticancer Drug Candidates NHC-AuCl and NHC-AuSR
Letters in Drug Design & Discovery The Cytoskeleton as a Therapeutic Target in Childhood Acute Leukemia:Obstacles and Opportunities
Current Drug Targets The Osteopontin Tissue Level as a Breast Cancer Biomarker in Females After Mastectomy Measured by the Capillary Gel Electrophoresis Technique
Combinatorial Chemistry & High Throughput Screening Gemini Surfactant Based Carriers in Gene and Drug Delivery
Current Medicinal Chemistry Gene Therapy Using an Adenovirus Vector for Apoptosis-Related Genes is a Highly Effective Therapeutic Modality for Killing Glioma Cells
Current Gene Therapy VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
Current Medicinal Chemistry Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS)
Recent Patents on Anti-Cancer Drug Discovery The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry BRCA Unclassified Variants: How Can They be Classified?
Current Women`s Health Reviews An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Current Pharmaceutical Design Therapeutics Based on microRNA: A New Approach for Liver Cancer
Current Genomics The Emerging Picture of CDK11: Genetic, Functional and Medicinal Aspects
Current Medicinal Chemistry Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research
Current Drug Targets Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Polymers and Drug Delivery Systems
Current Drug Delivery